{"id":11455,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:51:33","modified_gmt":"2025-10-04T08:51:33","slug":"hiperterminin-yasam-kalitesine-yk","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/tr\/hiperterminin-yasam-kalitesine-yk\/","title":{"rendered":"Hiperterminin Ya\u015fam Kalitesine (YK) Etkisi: A\u011fr\u0131 Giderimi, Yorgunluk Azalmas\u0131 ve Adjuvan \u0130mm\u00fcnolojik Faydalar"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Hiperterminin Ya\u015fam Kalitesine (YK) Etkisi: A\u011fr\u0131 Giderimi, Yorgunluk Azalmas\u0131 ve Adjuvan \u0130mm\u00fcnolojik Faydalar\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrul Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hipertermi, Onkoloji, Faz III klinik \u00e7al\u0131\u015fma, YK, a\u011fr\u0131, E-E-A-T\"\n      \/*... FAQPage \u015eemas\u0131 S\u0131k\u00e7a Sorulan Sorular b\u00f6l\u00fcm\u00fc i\u00e7in ayr\u0131 olarak eklenecektir *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Otorite ve Uzmanl\u0131k (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Yazan: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/tr\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, ve <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/tr\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hiperterminin Ya\u015fam Kalitesine (YK) Etkisi: A\u011fr\u0131 Giderimi, Yorgunluk Azalmas\u0131 ve Adjuvan \u0130mm\u00fcnolojik Faydalar<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Modern onkolojide, kanser y\u00f6netimi<a href=\"https:\/\/andromedichyperthermia.com\/tr\/hipertermi-kanser-hastalarinda-sagkalim\/\"> Sa\u011fkal\u0131m (OS\/DFS)<\/a> ve <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ya\u015fam Kalitesi (YK)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> aras\u0131nda optimal dengeyi hedefler. Hipertermi (HT), b\u00fcy\u00fck klinik \u00e7al\u0131\u015fmalarla ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/tr\/hiperterminin-faz-iii-calismalarinin\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Faz III RCT&#8217;ler<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) kan\u0131tlanm\u0131\u015f, semptom kontrol\u00fc, genel fonksiyonel durum ve m\u00fckemmel bir g\u00fcvenlik profili gibi \u00e7oklu seviyelerde YK&#8217;y\u0131 iyile\u015ftiren benzersiz bir adjuvan modalitedir.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Ba\u015fl\u0131ca Palyatif Fayda: A\u011fr\u0131 Kontrol\u00fc (Faz III klinik \u00e7al\u0131\u015fmalardan d\u00fczey A1 kan\u0131t\u0131)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastatik kemik a\u011fr\u0131s\u0131 YK&#8217;y\u0131 d\u00fc\u015f\u00fcr\u00fcr. Lokoregional RF Hipertermi, Radyoterapi (RT) ile kombine edildi\u011finde, Chi MS ve ark. taraf\u0131ndan yay\u0131nlanan Faz III \u00e7al\u0131\u015fmaya g\u00f6re \u00fcst\u00fcn palyatif kontrol sa\u011flar (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">YK G\u00f6stergesi\/A\u011fr\u0131 \u0130yile\u015fmesi<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapi<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermi (HT)<\/span><\/span><\/th>\n<th>YK Etkisi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3 Ayda Komple Komple Cevap Oran\u0131 (CR)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (s\u0131f\u0131r a\u011fr\u0131 skoru)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Toplam a\u011fr\u0131 giderimi \u015fans\u0131nda %533 art\u0131\u015f.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A\u011fr\u0131 Giderim S\u00fcresi<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medyan: 55 g\u00fcn\/7,9 hafta<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medyan: 24 haftada ula\u015f\u0131lamad\u0131<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Giderim s\u00fcresi \u00fc\u00e7 kat\u0131na \u00e7\u0131karak, a\u011fr\u0131 kesicilere ba\u011f\u0131ml\u0131l\u0131\u011f\u0131 azalt\u0131r.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024 y\u0131l\u0131nda Sahinbas ve meslekta\u015flar\u0131, WBHT wIRA hipertermisi ile RT&#8217;ye ek olarak meme ve prostat kanserinden kaynaklanan kemik metastaz a\u011fr\u0131lar\u0131 i\u00e7in bir Faz III \u00e7al\u0131\u015fmas\u0131 yay\u0131nlad\u0131lar.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Bu \u00e7al\u0131\u015fmaya g\u00f6re, sadece radyoterapi (RT) ile tedavi edilen grup en yo\u011fun a\u011fr\u0131y\u0131 g\u00f6sterdi. \u00c7al\u0131\u015fma, ilk kay\u0131ttan 5 y\u0131l sonra (Nisan 2016 \u2013 \u015eubat 2021) toplam 61 hasta kaydedilerek tamamland\u0131. Sonu\u00e7 olarak, RT + WBH grubundaki CR oran\u0131, RT&#8217;ye g\u00f6re en anlaml\u0131 fark\u0131 g\u00f6sterdi, tedavi sonras\u0131 2 ay i\u00e7inde s\u0131ras\u0131yla %47,4&#8217;e kar\u015f\u0131 %5,3 (P de\u011feri &lt; 0,05). Tam a\u011fr\u0131 giderim s\u00fcresi RT + WBH i\u00e7in 10 g\u00fcn iken, sadece RT grubunda son nokta zaman\u0131 kar\u015f\u0131lanamad\u0131. A\u011fr\u0131 ilerlemesi veya hastal\u0131k stabilitesi, RT grubundaki hastalar\u0131n yar\u0131s\u0131nda tedavi sonras\u0131 4 hafta i\u00e7inde g\u00f6zlendi. Ancak bu skor, RT + WBHT hastalar\u0131nda tedavi sonras\u0131 iki ay i\u00e7inde s\u0131f\u0131ra yak\u0131nd\u0131.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sonu\u00e7lar:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH art\u0131 RT, metastatik kemik lezyonlar\u0131 olan hastalarda sadece RT&#8217;ye k\u0131yasla a\u011fr\u0131 gideriminde \u00f6nemli art\u0131\u015flar ve daha k\u0131sa yan\u0131t s\u00fcresi g\u00f6sterdi.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">YK G\u00f6stergesi\/A\u011fr\u0131 \u0130yile\u015fmesi<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT Monoterapi<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermi (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">YK Etkisi<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Komple Komple Cevap Oran\u0131 (CR) 2 ayda<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (s\u0131f\u0131r a\u011fr\u0131 skoru)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">%894 art\u0131\u015f<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * total a\u011fr\u0131 eliminasyonu \u015fans\u0131nda.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tam a\u011fr\u0131 giderim s\u00fcresi<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">ula\u015f\u0131lmad\u0131<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 g\u00fcn<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00d6nemli ve H\u0131zl\u0131 Fayda<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">A\u011fr\u0131 Giderim S\u00fcresi\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medyan: 28 g\u00fcn\/4 hafta hastalar\u0131n yar\u0131s\u0131nda<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medyan: 24 haftada ula\u015f\u0131lamad\u0131<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Giderim s\u00fcresi * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">alt\u0131 kat\u0131na \u00e7\u0131karak<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, a\u011fr\u0131 kesicilere ba\u011f\u0131ml\u0131l\u0131\u011f\u0131 azalt\u0131r.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Fonksiyonel Durumun \u0130yile\u015ftirilmesi ve Yorgunlu\u011fun Azalt\u0131lmas\u0131<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT&#8217;nin YK \u00fczerindeki faydas\u0131, standardize edilmi\u015f anketler (EORTC QLQ-C30) arac\u0131l\u0131\u011f\u0131yla do\u011frudan \u00f6l\u00e7\u00fclebilir, genel durumda (Fiziksel Fonksiyon, Yorgunluk ve Anksiyete) bir iyile\u015fme g\u00f6sterir:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Anlaml\u0131 \u015eekilde \u0130yile\u015fmi\u015f YK (mod\u00fcle edilmi\u015f RF hipertermisi mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Serviks Kanserinde (LACC) Mod\u00fcle Edilmi\u015f RF Hipertermi (mEHT) \u00fczerine yap\u0131lan randomize klinik bir \u00e7al\u0131\u015fma, uzun vadeli YK skorlar\u0131nda anlaml\u0131 bir iyile\u015fme bildirmi\u015ftir; hastalar Fiziksel ve Duygusal Fonksiyon skalalar\u0131nda daha iyi skorlar rapor etmi\u015ftir.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Yorgunluk Kontrol\u00fc ve \u0130mm\u00fcnmod\u00fclasyon:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> T\u00fcm V\u00fccut Hipertermisi (WBHT) ve genel olarak HT, pro-inflamatuar sitokinleri (IL-6, TNF-alfa) mod\u00fcle ederek kronik yorgunlu\u011fu (CRF) pozitif olarak etkiler. HT ayr\u0131ca Fiziksel ve Duygusal Fonksiyon skalalar\u0131ndaki skorlar\u0131n uzun vadede korunmas\u0131na ve iyile\u015ftirilmesine yard\u0131mc\u0131 olur.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">H\u0131zl\u0131 Duygusal \u0130yile\u015fme (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> HT&#8217;yi i\u00e7eren b\u00fcy\u00fck cerrahi prosed\u00fcrlerden (HIPEC) sonra, duygusal YK h\u0131zla iyile\u015fme e\u011filimindedir, genellikle ameliyat sonras\u0131 3 ay gibi erken bir zamanda ba\u015flar ve bazen ba\u015flang\u0131\u00e7 seviyelerini a\u015far.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Uzun S\u00fcreli YK Faydalar\u0131n\u0131n Peki\u015ftirilmesi<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ger\u00e7ek d\u00fcnya verileri ve ileri evre kanserlerdeki klinik \u00e7al\u0131\u015fmalar, Hiperterminin uzun vadeli YK&#8217;y\u0131 stabilize etme ve iyile\u015ftirme rol\u00fcn\u00fc peki\u015ftirmektedir:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">12 Ayda Kuratif Etki:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Kuratif niyetle tedavi edilen hastalar\u0131n (RCT + HT) kapsaml\u0131 bir analizi, EORTC onkoloji referans pop\u00fclasyonuna k\u0131yasla *12 ayl\u0131k bir s\u00fcre boyunca* korunan, *Duygusal Fonksiyon, Sosyal Fonksiyon* ve *Uykusuzluk (SL)*&#8217;u de\u011ferlendiren YK alt \u00f6l\u00e7eklerindeki skorlarda anlaml\u0131 bir iyile\u015fme g\u00f6stermi\u015ftir.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palyatif Faydalar:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Palyatif bir ba\u011flamda, HT&#8217;nin standart tedaviye eklenmesi, tedavi sonras\u0131 *3 ayda* *A\u011fr\u0131 (PA)&#8217;da klinik olarak ilgili bir iyile\u015fmeye ve **Finansal Zorluklarda (FI)* azalmaya yol a\u00e7arak, hastan\u0131n daha iyi genel durumuna katk\u0131da bulunmu\u015ftur.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0130lerlemi\u015f Hastal\u0131kta \u0130yile\u015fmi\u015f YK (Kolorektal Kanser):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Orta ve ileri evre Kolorektal Kanser hastalar\u0131nda Kemoterapi Destekli Y\u00fcksek Frekansl\u0131 Hipertermiyi de\u011ferlendiren bir \u00e7al\u0131\u015fmada, kombinasyonu alan grup, 4 tedavi k\u00fcr\u00fcnden sonra anlaml\u0131 derecede daha y\u00fcksek (iyile\u015fmi\u015f) YK skorlar\u0131 g\u00f6stererek, HT&#8217;nin terap\u00f6tik etkilere ek olarak YK&#8217;y\u0131 etkin bir \u015fekilde iyile\u015ftirdi\u011fini ve daha iyi g\u00fcvenli\u011fi korudu\u011funu kan\u0131tlam\u0131\u015ft\u0131r.[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvan Biyolojik Faydalar ve \u00dcst\u00fcn Terap\u00f6tik \u0130ndeks<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT, \u015fiddetli toksisite (Derece 3-4) riskini anlaml\u0131 \u00f6l\u00e7\u00fcde art\u0131rmadan tedavinin letalitesini maksimize eder, b\u00f6ylece y\u00fcksek bir Terap\u00f6tik \u0130ndeksi s\u00fcrd\u00fcr\u00fcr:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Onaylanm\u0131\u015f G\u00fcvenlik (Faz III klinik \u00e7al\u0131\u015fmalar):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Serviks Kanserindeki meta-analizler, akut veya ge\u00e7 toksisitede anlaml\u0131 bir fark olmad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir (RR Toksisite 1.01)[6]. G\u00fcvenlik profili Rektal Kanser[7] ve Pankreas Kanseri \u00e7al\u0131\u015fmalar\u0131nda korunur.[8]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Organ Korunumu:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Rektal Kanserinde, neoadjuvan kemoradyoterapiye HT eklenmesi, 5 y\u0131ll\u0131k Kolostomisiz Sa\u011fkal\u0131m\u0131 (CFS) %69,0&#8217;dan %87,7&#8217;ye y\u00fckseltir, bu da YK a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck bir fonksiyonel faydad\u0131r.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abscopal Etki (A\u015f\u0131 Benzeri):<\/strong> HT, imm\u00fcnojenik h\u00fccre \u00f6l\u00fcm\u00fcn\u00fc tetikler ve sitotoksik CD8+ T h\u00fccrelerini aktive eden Is\u0131 \u015eok Proteinlerini (HSP&#8217;ler) serbest b\u0131rak\u0131r. Bu sistemik imm\u00fcnolojik ilk ad\u0131m, rezid\u00fcel hastal\u0131\u011f\u0131n kontrol\u00fcne katk\u0131da bulunur ve \u00f6nemli bir adjuvan faydad\u0131r.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sonu\u00e7: Hasta Odakl\u0131 Terapi<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hiperterminin onkolojik protokole entegrasyonu, sadece Sa\u011fkal\u0131m\u0131 iyile\u015ftirmekle kalmay\u0131p, ayn\u0131 zamanda sa\u011flam semptom kontrol\u00fc sa\u011flayan ve Ya\u015fam Kalitesini koruyan, geli\u015fmi\u015f, kan\u0131ta dayal\u0131 bir stratejidir. A\u011fr\u0131 giderimi, yorgunluk kontrol\u00fc ve m\u00fckemmel g\u00fcvenlik profili, HT&#8217;yi onkoloji hastas\u0131n\u0131n b\u00fct\u00fcnsel bak\u0131m\u0131n\u0131n \u00f6nemli bir unsuru haline getirir.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hem etkinli\u011fi hem de Ya\u015fam Kalitesini en \u00fcst d\u00fczeye \u00e7\u0131karmak amac\u0131yla, Hipertermiyi protokol\u00fcn\u00fcze entegre etmek i\u00e7in uzmanlar\u0131m\u0131za dan\u0131\u015fman\u0131z\u0131 \u00f6neriyoruz.<\/span><\/span><\/strong><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT G\u00fcvencesi:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Bu i\u00e7erik, standart Ya\u015fam Kalitesi \u00f6l\u00e7\u00fcm ara\u00e7lar\u0131n\u0131 (EORTC QLQ-C30) kullanan, yay\u0131nlanm\u0131\u015f Faz III randomize ve prospektif klinik \u00e7al\u0131\u015fmalardan elde edilen verilere dayanmaktad\u0131r. Tam kaynak\u00e7alar, kaynak yay\u0131nlara do\u011frudan ba\u011flant\u0131larla entegre edilmi\u015ftir.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kaynaklar:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Otorite ve Uzmanl\u0131k (EEAT): Yazan: Dr. Veronica Iatan , MD, ve Cristian Gologan M.Sc , Andromedichyperthermia Hiperterminin Ya\u015fam Kalitesine (YK) Etkisi: A\u011fr\u0131 Giderimi, Yorgunluk Azalmas\u0131 ve Adjuvan \u0130mm\u00fcnolojik Faydalar Modern onkolojide, kanser y\u00f6netimi Sa\u011fkal\u0131m (OS\/DFS) ve Ya\u015fam Kalitesi (YK) aras\u0131nda optimal dengeyi hedefler. Hipertermi (HT), b\u00fcy\u00fck klinik \u00e7al\u0131\u015fmalarla ( Faz III RCT&#8217;ler ) kan\u0131tlanm\u0131\u015f, semptom&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[197,1031,32],"tags":[1066,1032,1033,1064,306,1034,795,1038,1065],"class_list":["post-11455","post","type-post","status-publish","format-standard","hentry","category-news-tr","category-studii-clinice-tr","category-uncategorized-tr","tag-agri","tag-calitatea-vietii-tr","tag-durere-tr","tag-faz-iii-klinik-calisma","tag-hipertermi","tag-hipertermie-oncologica-tr","tag-onkoloji","tag-studii-faza-iii-tr","tag-yk"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/11455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/comments?post=11455"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/11455\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/media?parent=11455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/categories?post=11455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/tags?post=11455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}